Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Fresenius Biotech GmbH |
---|---|
Information provided by: | Fresenius Biotech GmbH |
ClinicalTrials.gov Identifier: | NCT00351858 |
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer
Condition | Intervention | Phase |
---|---|---|
Breast Neoplasms Breast Cancer |
Drug: ertumaxomab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer |
Estimated Enrollment: | 40 |
Study Start Date: | July 2006 |
A multi-centre, phase II study of ertumaxomab in metastatic breast cancer patients who became progressive after hormonal therapy. Each eligible patient will receive three ascending doses of ertumaxomab, administered intravenously. Ertumaxomab will be administered as a 3-hour constant rate infusion with a dosing interval of 7 days. Each patient will participate in this study for up to 7 months (includes the up to 21 days screening period, 14 days treatment period, and up to 180 days/6 months follow-up), with 3-monthly post-study follow-up until the patient becomes progressive.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adequate hematological, liver and kidney function:
No history of relevant cardiovascular disease:
Contact: Tanja Schaller-Kranz, Dr. | +49 - (0)89 - 306 593 - 0 | clinicalstudies@fresenius-biotech.com |
Belgium | |
Jules Bordet Institute, Free University of Brussels | Recruiting |
Brussels, Belgium, 1000 | |
Contact: Fatima Cardoso, MD + 32 2 541 3190 fatima.cardoso@bordet.be | |
Study site | Recruiting |
., Belgium | |
Contact +49-89-30 65 93-17 clinicalstudies@fresenius-biotech.com | |
Italy | |
Study site | Recruiting |
., Italy | |
Contact +49-89-30 65 93-17 clinicalstudies@fresenius-biotech.com | |
Russian Federation | |
Study site | Recruiting |
., Russian Federation | |
Contact +49-89-30 65 93-17 clinicalstudies@fresenius-biotech.com |
Principal Investigator: | Fatima Cardoso, MD | Brussels |
Study ID Numbers: | FBT-IVREXBC 02, EudraT number: 2005-004294-21 |
Study First Received: | July 12, 2006 |
Last Updated: | March 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00351858 |
Health Authority: | Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment; Spain: Spanish Agency of Medicines; Russia: Pharmacological Committee, Ministry of Health; Italy: Ethics Committee |
Breast Cancer investigational drug drug therapy Antineoplastic Protocols Immunotherapy Metastatic breast cancer |
Advanced breast cancer Stage III to IV breast cancer Hormonal therapy refractory Failure of hormonal therapy Her-2/neu expressing breast cancer low to moderate Her-2/neu expression |
Antibodies Skin Diseases Breast Neoplasms Breast Diseases Immunoglobulins |
Neoplasms Neoplasms by Site |